Role of bile acid sequestrants in the treatment of type 2 diabetes

doi:10.4239/wjd.v1.i5.146

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 1, Issue 5

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5678)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

511

HTML

4519

Figures (1-1)

384

Tables (1-1)

264

Sum=5678

Nov 15, 2010 (publication date) through Jan 13, 2025

Times Cited of This Article

Times Cited (11)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Diabetes. Nov 15, 2010; 1(5): 146-152
Published online Nov 15, 2010. doi: 10.4239/wjd.v1.i5.146

Role of bile acid sequestrants in the treatment of type 2 diabetes

Kohzo Takebayashi, Yoshimasa Aso, Toshihiko Inukai

Kohzo Takebayashi, Yoshimasa Aso, Toshihiko Inukai, Department of Internal Medicine, Dokkyo Medical University Koshigaya Hospital, Koshigaya 343-8555, Japan

Author contributions: Takebayashi K wrote this manuscript; and Aso Y and Inukai T reviewed the manuscript.

Correspondence to: Kohzo Takebayashi, MD, Department of Internal Medicine, Dokkyo Medical University Koshigaya Hospital, 2-1-50, Minami-Koshigaya, Koshigaya, Saitama 343-8555, Japan. takeb@gmail.plala.or.jp

Telephone: +81-48-9651111 Fax: +81-48-9651127

Received: June 22, 2010
Revised: August 27, 2010
Accepted: September 3, 2010
Published online: November 15, 2010

Abstract

Cholestyramine is a first-generation bile acid sequestrant (BAS) and antihyperlipidemic agent that currently has limited use because of its relatively weak effect on lowering low density-lipoprotein (LDL)-cholesterol (C) and poor tolerability. The current first choice drugs for hyper-LDL-cholesterolemia are 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) because of their strong LDL-C lowering effects and efficacy in prevention of cardiovascular disease. However, after lowering the target levels of LDL-C in very high risk patients, combination therapy with statins and other antihyperlipidemic drugs may become more important for treatment of hyper-LDL-cholesterolemia. Second-generation BASs such as colesevelam and colestimide have a glucose-lowering effect and improved tolerance, which has led to re-evaluation of their utility in combination with statins or antidiabetic agents.

Keywords: Bile acid; Bile acid sequestrant; Type 2 diabetes